Northridge, CA and Cambridge, UK, 11 March 2015 – Link here. Avita Medical Ltd (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today the closing of a placement to sophisticated and institutional investors and launched a Share Purchase Plan (“SPP”). The placement raised $A5,042,280.00 through the issuance […]
March 11, 2015 | By Damian Garde – Link here. AmpliPhi BioSciences has lined up $13 million in private placement cash, selling stock and warrants to fund its pipeline of treatments for drug-resistant bacterial infections. The Richmond, VA, biotech is issuing nearly 79 million shares at $0.165 apiece to a group of investors including partner Intrexon ($XON), […]
March 10, 2015 05:07 PM Eastern Daylight Time. Link here. RICHMOND, Va. & LJUBLJANA, Slovenia & SYDNEY–(BUSINESS WIRE)–AmpliPhi BioSciences Corporation, (OTCQB: APHB), a global leader in bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into definitive purchase agreements of common stock and warrants with a group of institutional accredited investors, […]
Potential breakthrough treatment for chronic pain Part of $10m capital raising BioScience Managers achieved a 24.7% IRR in its previous fund – top decile performance of international private equity and venture capital fund managers. 20 February 2015, Melbourne, Australia: Leading healthcare fund manager BioScience Managers has invested $5 million in novel chronic pain treatment company Saluda […]
Saluda Medical secures $10 million in new financing New funding secured for Saluda Medical is set to open the next chapter in commercialising breakthrough treatment of chronic pain. Link here. Friday, 20 February 2015: Saluda Medical has today announced that it has received $10 million in Series B financing bringing a breakthrough treatment for chronic pain – […]
Northridge, CA and Cambridge, UK, 28 January 2015. Link here. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY) a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that the first patient has been enrolled in the Company’s Pivotal Phase III burn trial for ReCell®. The FDA-approved study is designed to confirm the safety and […]
By Dylan Bushell-Embling | Posted in Medical devices on 22 January, 2015 Australian Life Scientist. Link here. A new smart inhaler developed by respiratory technology company Nexus6 has been demonstrated to encourage child asthmatics to take medication. Children using the SmartTrack inhaler, which incorporates an audio reminder function into standard inhaler technology, were 180% more likely to […]
London Live – link here. Maleena Pone – 16th January 2015 Nicholas Fearon, known as ‘Pikki’, is a London-based film producer. With the support of the REX robot, Pikki will walk for the first time since he battled back from life threatening injuries he sustained in an accident 11 years ago. He was told by doctors […]
Bacteriophage-based Antibacterial Therapies to Treat Drug Resistant Infections Advancing towards Human Clinical Studies 2015 Uplisting to Major Exchange Expected Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, January 05, 2015 – Link here. AmpliPhi BioSciences Corporation (OTCQB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, provided an update to […]